AstraZeneca aims to get COVID-19 therapy into clinic in 2 months

AstraZeneca is planning to start a phase 1 clinical trial of a COVID-19 antibody therapy within two months. The commitment follows the signing of a deal that grants AstraZeneca an exclusive license to six anti-SARS-CoV-2 antibodies identified by researchers at Vanderbilt University.